Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer
Lung cancer is the leading cause of cancer death, and non-small cell lung cancer (NSCLC) accounts for 85%. Immunotherapy has significantly improved the clinical prognosis of patients with NSCLC. However, because of the complexity and heterogeneousness of the tumor microenvironment, only a subset of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2023-08-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.23 |
| _version_ | 1797672771334963200 |
|---|---|
| author | Ying LIU Lei XIONG Ruoxue CAI Yue CHEN Jinjun YE Bo SHEN Guoren ZHOU |
| author_facet | Ying LIU Lei XIONG Ruoxue CAI Yue CHEN Jinjun YE Bo SHEN Guoren ZHOU |
| author_sort | Ying LIU |
| collection | DOAJ |
| description | Lung cancer is the leading cause of cancer death, and non-small cell lung cancer (NSCLC) accounts for 85%. Immunotherapy has significantly improved the clinical prognosis of patients with NSCLC. However, because of the complexity and heterogeneousness of the tumor microenvironment, only a subset of individuals can benefit from immunotherapy. Therefore, it is necessary to explore effective predictive biomarkers for immunotherapy of NSCLC. Tertiary lymphoid structure (TLS) is an ectopic lymphoid organ that is highly similar to secondary lymphoid organs (SLO), and the presence of TLS has been found to be closely associated with a good prognosis in immunotherapy for a variety of solid tumors, including NSCLC. This article provides a review of the prognostic role of tertiary lymphoid structures in immunotherapy of NSCLC, in order to offer references for screening suitable candidates for immunotherapy of NSCLC and develop personalized and precise treatment plans. |
| first_indexed | 2024-03-11T21:36:02Z |
| format | Article |
| id | doaj.art-a824816b35e9457799f48b83749b85c0 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-03-11T21:36:02Z |
| publishDate | 2023-08-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-a824816b35e9457799f48b83749b85c02023-09-27T02:11:26ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872023-08-0126861562010.3779/j.issn.1009-3419.2023.101.23Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung CancerYing LIU0Lei XIONG1Ruoxue CAI2Yue CHEN3Jinjun YE4Bo SHEN5Guoren ZHOU6The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Nanjing 210009, ChinaGeneral Hospital of Eastern Theater Command, Nanjing 210002, ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Nanjing 210009, ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Nanjing 210009, ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Nanjing 210009, ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Nanjing 210009, ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Nanjing 210009, ChinaLung cancer is the leading cause of cancer death, and non-small cell lung cancer (NSCLC) accounts for 85%. Immunotherapy has significantly improved the clinical prognosis of patients with NSCLC. However, because of the complexity and heterogeneousness of the tumor microenvironment, only a subset of individuals can benefit from immunotherapy. Therefore, it is necessary to explore effective predictive biomarkers for immunotherapy of NSCLC. Tertiary lymphoid structure (TLS) is an ectopic lymphoid organ that is highly similar to secondary lymphoid organs (SLO), and the presence of TLS has been found to be closely associated with a good prognosis in immunotherapy for a variety of solid tumors, including NSCLC. This article provides a review of the prognostic role of tertiary lymphoid structures in immunotherapy of NSCLC, in order to offer references for screening suitable candidates for immunotherapy of NSCLC and develop personalized and precise treatment plans.http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.23tertiary lymphoid structurelung neoplasmsimmunotherapy |
| spellingShingle | Ying LIU Lei XIONG Ruoxue CAI Yue CHEN Jinjun YE Bo SHEN Guoren ZHOU Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer Chinese Journal of Lung Cancer tertiary lymphoid structure lung neoplasms immunotherapy |
| title | Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer |
| title_full | Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer |
| title_fullStr | Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer |
| title_full_unstemmed | Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer |
| title_short | Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer |
| title_sort | recent progress of tertiary lymphoid structure in prognosis and immunotherapy of non small cell lung cancer |
| topic | tertiary lymphoid structure lung neoplasms immunotherapy |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.23 |
| work_keys_str_mv | AT yingliu recentprogressoftertiarylymphoidstructureinprognosisandimmunotherapyofnonsmallcelllungcancer AT leixiong recentprogressoftertiarylymphoidstructureinprognosisandimmunotherapyofnonsmallcelllungcancer AT ruoxuecai recentprogressoftertiarylymphoidstructureinprognosisandimmunotherapyofnonsmallcelllungcancer AT yuechen recentprogressoftertiarylymphoidstructureinprognosisandimmunotherapyofnonsmallcelllungcancer AT jinjunye recentprogressoftertiarylymphoidstructureinprognosisandimmunotherapyofnonsmallcelllungcancer AT boshen recentprogressoftertiarylymphoidstructureinprognosisandimmunotherapyofnonsmallcelllungcancer AT guorenzhou recentprogressoftertiarylymphoidstructureinprognosisandimmunotherapyofnonsmallcelllungcancer |